Please login to the form below

Not currently logged in
Email:
Password:

Kymriah

This page shows the latest Kymriah news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts take centre stage as ASH18 comes to a close

CAR-Ts take centre stage as ASH18 comes to a close

Similarly, CAR-T pioneer Novartis reported longer-term data on Kymriah (tisagenlecleucel) in children with r/r ALL and adults with r/r diffuse large B-cell lymphoma (DLBCL) that it ... said “underscore the longer-term durability of response with

Latest news

More from news
Approximately 9 fully matching, plus 34 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October. ... Kymriah, which make it into routine practice as a first-line treatment.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics